{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T03:51:12Z","timestamp":1765079472262,"version":"3.37.3"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T00:00:00Z","timestamp":1648684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T00:00:00Z","timestamp":1648684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"DOI":"10.1007\/s10792-022-02261-1","type":"journal-article","created":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T14:03:45Z","timestamp":1648735425000},"page":"2729-2740","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The efficacy of different anti-vascular endothelial growth factor agents and prognostic biomarkers in monitoring of the treatment for myopic choroidal neovascularization"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7362-4453","authenticated-orcid":false,"given":"Bu\u011fra","family":"Karasu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali R\u0131za Cenk","family":"Celebi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,31]]},"reference":[{"key":"2261_CR1","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/00006982-199212020-00009","volume":"12","author":"HE Grossniklaus","year":"1992","unstructured":"Grossniklaus HE, Green WR (1992) Pathological findings in pathologic myopia. Retina 12:127\u2013133","journal-title":"Retina"},{"key":"2261_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1097\/00006982-199212010-00003","volume":"12","author":"L Pierro","year":"1992","unstructured":"Pierro L, Camesasca FI, Mischi M, Brancato R (1992) Peripheral retinal changes and axial myopia. Retina 12:12\u201317","journal-title":"Retina"},{"key":"2261_CR3","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/S0002-9394(14)76891-6","volume":"111","author":"JM Celorio","year":"1991","unstructured":"Celorio JM, Pruett RC (1991) Prevalence of lattice degeneration and its relation to axial length in severe myopia. Am J Ophthalmol 111:20\u201323","journal-title":"Am J Ophthalmol"},{"key":"2261_CR4","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.preteyeres.2012.04.001","volume":"31","author":"K Neelam","year":"2012","unstructured":"Neelam K, Cheung CMG, Ohno-Matsui K, Lai TYY, Wong TY (2012) Choroidal neovascularization in pathological myopia. Prog Retin Eye Res 31:495\u2013525","journal-title":"Prog Retin Eye Res"},{"key":"2261_CR5","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1016\/S0161-6420(96)30515-0","volume":"103","author":"SY Cohen","year":"1996","unstructured":"Cohen SY, Laroche A, Leguen Y, Soubrane G, Coscas GJ (1996) Etiology of choroidal neovascularization in young patients. Ophthalmology 103:1241\u20131244","journal-title":"Ophthalmology"},{"key":"2261_CR6","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1007\/s00417-006-0324-4","volume":"244","author":"A Kojima","year":"2006","unstructured":"Kojima A, Ohno-Matsui K, Teramukai S et al (2006) Estimation of visual outcome without treatment in patients with subfoveal choroidal neovascularization in pathologic myopia. Graefes Arch Clin Exp Ophthalmol 244:1474\u20131479","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2261_CR7","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1023\/A:1025488429802","volume":"24","author":"F Bottoni","year":"2001","unstructured":"Bottoni F, Tilanus M (2001) The natural history of Juxtafoveal and Subfoveal choroidal neovascularization in high myopia. Int Ophthalmol 24:249\u2013255","journal-title":"Int Ophthalmol"},{"issue":"2","key":"2261_CR8","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1136\/bjo.87.2.173","volume":"87","author":"JA Montero","year":"2003","unstructured":"Montero JA, Ruiz-Moreno JM (2003) Verteporfin photodynamic therapy in highly myopic subfoveal choroidal neovascularisation. Br J Ophthalmol 87(2):173\u2013176","journal-title":"Br J Ophthalmol"},{"key":"2261_CR9","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1097\/IAE.0b013e3181b1bb1a","volume":"29","author":"SY Cohen","year":"2009","unstructured":"Cohen SY (2009) Anti-VEGF drugs as the 2009 first-line therapy for choroidal neovascularization in pathologic myopia. Retina 29:1062\u20131066","journal-title":"Retina"},{"key":"2261_CR10","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1097\/IAE.0b013e31826956b7","volume":"32","author":"P Iacono","year":"2012","unstructured":"Iacono P, Parodi MB, Papayannis A et al (2012) Intravitreal ranibizumab versus bevacizumab for treatment of myopic choroidal neovascularization. Retina 32:1539\u20131546","journal-title":"Retina"},{"issue":"1","key":"2261_CR11","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ajo.2009.01.024","volume":"148","author":"GA Lalwani","year":"2009","unstructured":"Lalwani GA, Rosenfeld PJ, Fung AE et al (2009) A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 148(1):43\u201358","journal-title":"Am J Ophthalmol"},{"key":"2261_CR12","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1097\/ALN.0b013e31823d7784","volume":"116","author":"JM Bland","year":"2012","unstructured":"Bland JM, Altman DG (2012) Agreed statistics: measurement method comparison. Anesthesiology 116:182\u2013185","journal-title":"Anesthesiology"},{"issue":"1","key":"2261_CR13","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s10384-014-0363-z","volume":"59","author":"SY Cohen","year":"2015","unstructured":"Cohen SY, Nghiem-Buffet S, Grenet T et al (2015) Long-term variable outcome of myopic choroidal neovascularization treated with ranibizumab. Jpn J Ophthalmol 59(1):36\u201342","journal-title":"Jpn J Ophthalmol"},{"issue":"7","key":"2261_CR14","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1097\/IAE.0b013e31827d260a","volume":"33","author":"E Wang","year":"2013","unstructured":"Wang E, Chen Y (2013) Intravitreal anti-vascular endothelial growth factor for choroidal neovascularization secondary to pathologic myopia: systematic review and meta-analysis. Retina 33(7):1375\u20131392","journal-title":"Retina"},{"key":"2261_CR15","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.ophtha.2013.10.023","volume":"121","author":"Wolf S, Balciuniene VJ, Laganovska G, RADIANCE Study Group et al.","year":"2014","unstructured":"Wolf S, Balciuniene VJ, Laganovska G, RADIANCE Study Group et al. (2014) RADIANCE: a randomised controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology 121:682\u2013692","journal-title":"Ophthalmology"},{"issue":"9","key":"2261_CR16","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1016\/j.ophtha.2013.06.010","volume":"120","author":"A Tufail","year":"2013","unstructured":"Tufail A, Narendran N, Patel PJ et al (2013) Ranibizumab in myopic choroidal neovascularization: the 12-month results from the REPAIR study. Ophthalmology 120(9):1944\u20131945","journal-title":"Ophthalmology"},{"issue":"4","key":"2261_CR17","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1055\/s-0032-1328366","volume":"230","author":"L Hefner","year":"2013","unstructured":"Hefner L, Riese J, Gerding H (2013) Three years follow-up results of ranibizumab treatment for choroidal neovascularization secondary to pathologic myopia. Klin Monatsbl Augenheilkd 230(4):401\u2013404","journal-title":"Klin Monatsbl Augenheilkd"},{"issue":"6","key":"2261_CR18","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1038\/eye.2009.88","volume":"23","author":"JM Mon\u00e9s","year":"2009","unstructured":"Mon\u00e9s JM, Amselem L, Serrano A, Garcia M, Hijano M (2009) Intravitreal ranibizumab for choroidal neovascularization secondary to pathologic myopia: 12-month results. Eye (Lond) 23(6):1275\u201380","journal-title":"Eye (Lond)"},{"key":"2261_CR19","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.ophtha.2015.01.025","volume":"122","author":"Y Ikuno","year":"2015","unstructured":"Ikuno Y, Ohno-Matsui K, Wong TY, Investigators MYRROR et al (2015) Intravitreal aflibercept injection in patients with myopic choroidal neovascularization: the MYRROR study. Ophthalmology 122:1220\u20131227","journal-title":"Ophthalmology"},{"key":"2261_CR20","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/nature04483","volume":"438","author":"N Ferrara","year":"2005","unstructured":"Ferrara N, Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature 438:967\u2013974","journal-title":"Nature"},{"key":"2261_CR21","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1007\/s00417-014-2719-y","volume":"252","author":"A Klettner","year":"2014","unstructured":"Klettner A, Recber M, Roider J (2014) Comparison of the efficacy of aflibercept, ranibizumab, and bevacizumab in an RPE\/choroid organ culture. Graefes Arch Clin Exp Ophthalmol 252:1593\u20131598","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2261_CR22","doi-asserted-by":"publisher","first-page":"5","DOI":"10.4081\/eye.2011.e5","volume":"1","author":"MW Stewart","year":"2011","unstructured":"Stewart MW (2011) What are the half-lives of ranibizumab and aflibercept (Trap-eye VEGF) in human eyes? Calculations with a mathematical model. Eye Rep 1:5","journal-title":"Eye Rep"},{"issue":"4","key":"2261_CR23","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.ajo.2012.03.047","volume":"154","author":"TU Krohne","year":"2012","unstructured":"Krohne TU, Liu Z, Holz FG, Meyer CH (2012) Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans. Am J Ophthalmol 154(4):682-686.e2","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"2261_CR24","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1167\/iovs.16-19204","volume":"57","author":"SJ Park","year":"2016","unstructured":"Park SJ, Choi Y, Na YM et al (2016) Intraocular pharmacokinetics of intravitreal Aflibercept (Eylea) in a rabbit model. Investig Ophthalmol Vis Sci 57(6):2612\u20132617","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"12","key":"2261_CR25","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1080\/17425255.2017.1404987","volume":"13","author":"M Edington","year":"2017","unstructured":"Edington M, Connolly J, Chong NV (2017) Pharmacokinetics of intravitreal anti-VEGF drugs in vitrectomized versus non-vitrectomized eyes. Expert Opin Drug Metab Toxicol 13(12):1217\u20131224","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"2261_CR26","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/IAE.0000000000000265","volume":"35","author":"TU Krohne","year":"2015","unstructured":"Krohne TU, Muether PS, Stratmann NK et al (2015) Influence of ocular volume and lens status on pharmacokinetics and duration of action of intravitreal vascular endothelial growth factor inhibitors. Retina 35(1):69\u201374","journal-title":"Retina"},{"key":"2261_CR27","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1016\/j.ophtha.2007.09.012","volume":"114","author":"SJ Bakri","year":"2007","unstructured":"Bakri SJ, Snyder MR, Reid JM et al (2007) Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 114:2179\u20132182","journal-title":"Ophthalmology"},{"key":"2261_CR28","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1097\/IAE.0b013e318134eecd","volume":"27","author":"J Gaudreault","year":"2007","unstructured":"Gaudreault J, Fei D, Beyer JC et al (2007) Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits. Retina 27:1260\u20131266","journal-title":"Retina"},{"key":"2261_CR29","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1111\/j.1442-9071.2011.02684.x","volume":"40","author":"DS Ng","year":"2012","unstructured":"Ng DS, Kwok AKH, Chan CW (2012) Anti-vascular endothelial growth factor for myopic choroidal neovascularization. Clin Exp Ophthalmol 40:e98\u2013e110","journal-title":"Clin Exp Ophthalmol"},{"key":"2261_CR30","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1007\/s00417-016-3396-9","volume":"254","author":"A Peace","year":"2016","unstructured":"Peace A, Milani P (2016) Intravitreal aflibercept for myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 254:2327\u20132332","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2261_CR31","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s00417-018-04214-w","volume":"257","author":"K Sayanagi","year":"2019","unstructured":"Sayanagi K, Uematsu S, Hara C et al (2019) Effect of intravitreal injection of aflibercept or ranibizumab on chorioretinal atrophy in myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 257:749\u2013757","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2261_CR32","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/1471-2415-14-69","volume":"14","author":"DM Cha","year":"2014","unstructured":"Cha DM, Kim TW, Heo JW et al (2014) Comparison of 1-year therapeutic effect of ranibizumab and bevacizumab for myopic choroidal neovascularization: a retrospective, multicenter, comparative study. BMC Ophthalmol 14:69","journal-title":"BMC Ophthalmol"},{"issue":"7","key":"2261_CR33","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1038\/eye.2012.97","volume":"26","author":"TYY Lai","year":"2012","unstructured":"Lai TYY, Luk FOJ, Lee GKY, Lam DSC (2012) Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization. Eye (Lond) 26(7):1004\u20131011","journal-title":"Eye (Lond)"},{"issue":"5","key":"2261_CR34","doi-asserted-by":"publisher","first-page":"577","DOI":"10.5301\/ejo.5000936","volume":"27","author":"AA El-Shazly","year":"2017","unstructured":"El-Shazly AA, Farweez YA, El-Sebaay ME, El-Zawahry WMA (2017) Correlation between choroidal thickness and degree of myopia assessed with enhanced depth imaging optical coherence tomography. Eur J Ophthalmol 27(5):577\u2013584","journal-title":"Eur J Ophthalmol"},{"issue":"2","key":"2261_CR35","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.ajo.2012.07.015","volume":"155","author":"I Flores-Moreno","year":"2013","unstructured":"Flores-Moreno I, Lugo F, Duker JS, Ruiz-Moreno JM (2013) The relationship between axial length and choroidal thickness in eyes with high myopia. Am J Ophthalmol 155(2):314\u2013319","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"2261_CR36","doi-asserted-by":"publisher","first-page":"e709","DOI":"10.1111\/aos.13084","volume":"94","author":"P Gupta","year":"2016","unstructured":"Gupta P, Cheung CY, Saw S-M et al (2016) Choroidal thickness does not predict visual acuity in young high myopias. Acta Ophthalmol 94(8):e709\u2013e715","journal-title":"Acta Ophthalmol"},{"issue":"3","key":"2261_CR37","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3109\/02713683.2014.973043","volume":"40","author":"W Chen","year":"2015","unstructured":"Chen W, Song H, Xie S, Han Q, Tang X, Chu Y (2015) Correlation of macular choroidal thickness with concentrations of aqueous vascular endothelial growth factor in high myopia. Curr Eye Res 40(3):307\u201313","journal-title":"Curr Eye Res"},{"key":"2261_CR38","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.ophtha.2006.11.034","volume":"114","author":"M Moriyama","year":"2007","unstructured":"Moriyama M, Ohno-Matsui K, Futagami S et al (2007) Morphology and long-term changes of choroidal vascular structure in highlymyopic eyes with and without posterior staphyloma. Ophthalmology 114:1755\u20131762","journal-title":"Ophthalmology"},{"issue":"13","key":"2261_CR39","doi-asserted-by":"publisher","first-page":"9555","DOI":"10.1167\/iovs.11-8076","volume":"52","author":"X Ding","year":"2011","unstructured":"Ding X, Li J, Zeng J et al (2011) Choroidal thickness in healthy Chinese subjects. Investig Ophthalmol Vis Sci 52(13):9555\u20139560","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"1","key":"2261_CR40","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ophtha.2012.07.048","volume":"120","author":"WB Wei","year":"2013","unstructured":"Wei WB, Xu L, Jonas JB et al (2013) Subfoveal choroidal thickness: the Beijing eye study. Ophthalmology 120(1):175\u201380","journal-title":"Ophthalmology"},{"key":"2261_CR41","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2353\/ajpath.2007.061237","volume":"171","author":"K Nishijima","year":"2007","unstructured":"Nishijima K, Ng Y-S, Zhong L et al (2007) Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 171:53\u201367","journal-title":"Am J Pathol"},{"key":"2261_CR42","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/00006982-200502000-00001","volume":"25","author":"AP Adamis","year":"2005","unstructured":"Adamis AP, Shima DT (2005) The role of vascular endothelial growth factor in ocular health and disease. Retina 25:111\u2013118","journal-title":"Retina"},{"key":"2261_CR43","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1007\/s10384-012-0128-5","volume":"56","author":"A Fujiwara","year":"2012","unstructured":"Fujiwara A, Shiragami C, Shirakata Y, Manabe S, Izumibata S, Shiraga F (2012) Enhanced depth imaging spectral-domain optical coherencetomography of subfovealchoroidal thickness in normalJapanese eyes. Jpn J Ophthalmol 56:230\u2013235","journal-title":"Jpn J Ophthalmol"},{"key":"2261_CR44","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.ophtha.2013.06.013","volume":"121","author":"QS You","year":"2014","unstructured":"You QS, Peng XY, Xu L, Chen CX, Wang YX, Jonas JB (2014) Myopic maculopathy imaged by optical coherence tomography: the Beijing eye study. Ophthalmology 121:220\u2013224","journal-title":"Ophthalmology"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-022-02261-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-022-02261-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-022-02261-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T16:09:32Z","timestamp":1661616572000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-022-02261-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,31]]},"references-count":44,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["2261"],"URL":"https:\/\/doi.org\/10.1007\/s10792-022-02261-1","relation":{},"ISSN":["1573-2630"],"issn-type":[{"type":"electronic","value":"1573-2630"}],"subject":[],"published":{"date-parts":[[2022,3,31]]},"assertion":[{"value":"19 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Author Bugra Karasu declares that he has no conflict of interest. Author Ali R\u0131za Cenk Celebi declares that he has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained prior to every surgical procedure from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}